RAPHRaphael Pharmaceutical Inc.vs its industry peers
A metric-by-metric comparison of Raphael Pharmaceutical Inc. against SIC 2833 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RAPHEsta | — | — | — | — | — | 15.8%#4 | — | — | — | — | — | — |
| JUSH | — | — | — | — | 2.1%#4 | -40.6%#8 | 1.8%#1 | — | 8.8%#1 | 3#3 | — | — |
| LEEEF | — | — | — | — | 22.1%#2 | 28.4%#2 | -21.8%#4 | — | — | — | — | — |
| MDWD | $177M#1 | — | — | 10.4x#1 | -16.1%#7 | 21.0%#3 | -149.0%#5 | — | — | — | -22.9%#1 | — |
| MRMD | — | — | — | — | 1.3%#5 | -16.2%#7 | -1.8%#2 | -17.5%#1 | -1.7%#2 | 3#3 | — | — |
| NPHC | — | — | — | — | 4.6%#3 | -59.2%#9 | -567.7%#8 | — | — | 2#6 | — | — |
| NTRR | — | — | — | — | -26.1%#8 | 11.3%#6 | -437.8%#7 | — | — | 3#3 | — | — |
| PLSH | — | — | — | — | 46.6%#1 | 12.3%#5 | -232.5%#6 | — | — | 4#1 | — | — |
| RAJAF | — | — | — | — | -0.6%#6 | 31.6%#1 | -11.3%#3 | — | — | 4#1 | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2833). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. Esta tabla agotó el tiempo durante su construcción, por lo que cubre parte del grupo; los rangos son solo dentro de las filas mostradas y se completará en breve. Table built 2026-09-22.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice